Hemodialysis and hemodiafiltration-induced transient hypercalcemia: an unrecognized phenomenon with potential for calcium-loss and vascular calcification

Kamel El-Reshaid *, Shaikha Al-Bader **, Salah El-Marzabani ***, Ehab Ahmad **

* Department of Medicine, Faculty of Medicine, Kuwait University, Kuwait
** Department of Medicine, Nephrology unit, Amiri hospital, Ministry of health, Kuwait
*** Edelia dialysis center, Ministry of health, Kuwait

INTRODUCTION

Uremic vascular calcification (VC) was first reported more than 100 years ago. Subsequently, such association was confirmed in autopsy studies between 1855 and 1945. VC is common in patients with end-stage kidney disease (ESRD) with a prevalence of 70%–80%. The adjusted cardiovascular mortality, in this patient population, is 10 to 20 times higher than in the general population and multiple studies have demonstrated that VC is an independent predictor of cardiovascular morbidity and mortality. VC occurs in two distinct sites, the intimal and medial layers. Intimal calcification is associated with atherosclerotic stenotic plaques and medial calcification with vascular stiffening and peripheral ischemia. Though both forms of calcification can develop in renal patients, medial one is more common. Traditionally, VC was considered a passive process associated with advanced age, atherosclerosis, uncommon genetic diseases and some metabolic alterations such as diabetes mellitus and ESRD. However, recent studies have disclosed cellular inflammation induced by VC, in genetically predisposed individuals, leading to transformation of vascular smooth muscle cells (VSMC) into osteochondrogenic ones. The mechanisms of such vascular calcification include: (a) genetic predisposition to deposition of bioapatite crystals in VSMC following oversaturation with calcium (Ca) and phosphate, (b) uremic injury to the matrix vesicles of VSMC, by bioapatite deposition, leading to local apoptosis, (c) loss of inhibitors of calcification by uremia viz. matrix GLa protein, fetuin A, osteopontin, osteoprotegerin, and finally (d) induction of uremic calcification-activators leading to transformation of VSMC to osteoblasts viz. TNF, 25 hydroxycholesterol, cytokines, fibronectin. Hence, efforts aimed at limiting uremic VC may improve survival in patients’ population. This study was conducted to assess a potential role of 2 common blood purification therapy (BPT) viz. maintenance hemodialysis (HD) and hemodiafiltration (HDF) in induction of hypercalcemia and the benefit of bisphosphonate in stabilizing this phenomenon.

PATIENTS AND METHODS

The study was conducted at Edelia dialysis unit. The latter is the main satellite dialysis unit for the capital area of Kuwait city. It has adequate laboratory diagnostic as well as therapeutic facilities to care for ESRD patients with different modalities of dialysis. Patients were included in the study if they were; (a) adults, (b) with efficient hemodialysis access, (c) with stable cardiovascular status, (d) compliant with both medical and BPT for a minimum of 12 months. The studied patients had controlled predialysis levels of calcium, phosphorus, 1, 25 vitamin D and parathyroid hormone. Treatment was associated with high diysate calcium and low serum phosphorus without significant changes in parathyroid hormone levels. Pre-treatment with a single dose of Fosamax; resulted in amelioration of hypercalcemia indicating its bone etiology. In conclusion; maintenance HD and HDF are associated with inherent hypercalcemia which may contribute to osteomalacia and uremic vascular calcification in ESRD patients.

Keywords: Bisphosphonates, HD, HDF, hypercalcemia, hypophosphatemia, osteomalacia, vascular calcification, uremia.
their renal osteodystrophy. All had normal levels of 1, 25 dihydroxyvitamin D.

**HD technique:**

Using Gambro 200 Ultra S machines; sessions were done for 4 hours 3 times/week using cuprophan low-flux hemofilters with ultrafiltration coefficient at 5.5 ml/hour/mmHg. Blood and dialysate flow rates were 200 ml/min and 350 ml/min, respectively.

**HDF technique:**

Using Fresenius 5008 machines; sessions were done for 4 hours 3 times/week using Nephral 400 ST high-flux filters (AN69 ST membrane with ultrafiltration coefficient at 50 ml/hour/mmHg). Blood speed was set at 200 ml/minute and dialysate flow at 500 ml/minute.

**Initial assessment:**

Included laboratory testing for corrected serum Ca, ionized Ca (iCa), P, bicarbonate (HCO₃⁻) before starting BPT (time 0) then at the end of the session 4 hours later (time 4) then 4 hours after termination of BPT session (time 8). Intact parathyroid hormone (PTH) was tested at time 0 and time 8. From the previous results; CaXP was calculated at times 0, 4 and 8 hours.

**Subsequent testing:**

All patients had received 1 tablet of Fosamax (Alendronate sodium) 70 mg at early morning on empty stomach and with ½ cup of water before and after. For ½ hour; patients were instructed to avoid lying down. Subsequently, patients had BPT every other day X 3 and on the 6th day (3rd hemodialysis session); all the initial tests and calculations were repeated.

**Statistical analysis:**

SPSS statistical package version 25 was used for data entry and processing. The p-value ≤ 0.05 was used as the cut-off level for significance. Since the age, duration of prior hemodialysis were not normally distributed; the median and (Interquartile Range) were used to express the groups. Mann-Whitney U test was used to compare groups of gender and type of renal disease while Wilcoxon Signed Rank test was to compare laboratory data prior Fosamax therapy with that subsequent to it.

**RESULTS**

Two groups of patients were studied viz. those on maintenance HD and HDF.

**Demographical data:**

In the HD group a total of 105 patients were included. Their age was 50(9) years. In this group; males were 52 (49.5%), diabetics 57 (54.3%) and they had received maintenance therapy for 23(10) months. In the HDF group a total of 44 patients were included. Their age was 51(6) years. In this group; males were 22 (50%), diabetics 23 (52.3%) and they had received maintenance therapy for 17(4) months.

**Changes in serum electrolytes during HD and HDF:**

Serum electrolytes and PTH levels at (4 hours and 8 hours) are summarized in Table 1. Levels of (serum Ca, iCa, HCO₃⁻) had increased and levels of (serum P, CaXP) had decreased by 4 hours then, by 8 hours, such changes were less but did not reach their starting levels (p < 0.001). PTH levels did not change significantly. Pretreatment with Fosamax resulted in milder changes yet not in P levels. The results were not different with respect to gender and type of renal disease.

| Table 1: Electrolytes changes during hemodialysis and hemodiafiltration before and after Fosamax treatment. |
|---------------------------------------------------------------|
| **HD group (n= 105):** | **A- Before Fosamax:** | **B- After Fosamax:** |
| Ca 0 | Ca 4 | Ca 8 | Ca 0 | Ca 4 | Ca 8 |
| 2.30(1) | 2.70(2) | 2.52(1) | 2.30(1) | 2.60(2) | 2.42(2) |
| Ca 0 | Ca 4 | Ca 8 | Ca 0 | Ca 4 | Ca 8 |
| iCa 0 | iCa 4 | iCa 8 | iCa 0 | iCa 4 | iCa 8 |
| 1.15(0.05) | 1.35(0.1) | 1.25(0.05) | 1.15(0.05) | 1.30(0.08) | 1.20(1) |
| P | P | P | P | P | P |
| 1.60(5) | 1.10(4) | 1.30(4) | 1.60(5) | 1.10(4) | 1.20(1) |
| Ca X P | Ca X P | Ca X P | Ca X P | Ca X P | Ca X P |
| 3.51(24) | 2.80(9) | 3.21(1) | 3.51(1) | 2.6(1) | 3.0(1) |
| HCO₃⁻ | HCO₃⁻ | HCO₃⁻ | HCO₃⁻ | HCO₃⁻ | HCO₃⁻ |
| 18(2) | 27(2) | 26(1) | 18(3) | 27(2) | 26(1) |
| PTH | PTH | PTH | PTH | PTH | PTH |
| 26(5) | 28(3) | 28(4) | 26(5) | 28(3) | 28(4) |

| **HDF group (n= 44):** | **A- Before Fosamax:** | **B- After Fosamax:** |
| Ca 0 | Ca 4 | Ca 8 | Ca 0 | Ca 4 | Ca 8 |
| 2.30(1) | 2.60(1) | 2.52(1) | 2.30(1) | 2.52(1) | 2.42(2) |
| Ca 0 | Ca 4 | Ca 8 | Ca 0 | Ca 4 | Ca 8 |
| iCa 0 | iCa 4 | iCa 8 | iCa 0 | iCa 4 | iCa 8 |
| 1.20(0) | 1.30(05) | 1.25(05) | 1.20(05) | 1.25(05) | 1.20(05) |
| P | P | P | P | P | P |
| 1.50(1) | 0.80(2) | 1.20(1) | 1.50(2) | 0.80(2) | 1.20(1) |
| Ca X P | Ca X P | Ca X P | Ca X P | Ca X P | Ca X P |
| 3.50(4) | 2.20(5) | 2.80(4) | 3.50(3) | 2.60(5) | 2.80(4) |
| HCO₃⁻ | HCO₃⁻ | HCO₃⁻ | HCO₃⁻ | HCO₃⁻ | HCO₃⁻ |
| 18(1) | 26(2) | 25(2) | 18(1) | 26(1) | 25(1) |
| PTH | PTH | PTH | PTH | PTH | PTH |
| 26(2) | 28(3) | 28(4) | 26(5) | 28(3) | 28(4) |

Abbreviations: corrected serum calcium (Ca), ionized calcium (iCa), phosphorus (P), bicarbonate (HCO₃⁻), parathyroid hormone (PTH).

Time of testing with regards dialytic therapy: at start (0), 4 hours later (4), 8 hours later (8)
Changes in composition of electrolytes in dialysate fluid during HD and HDF:

The changes in iCa, P and HCO at start of therapy and by 4 hours are summarized in Table 2. As expected; P content had increased significantly yet iCa had increased also. Again; changes were less after pretreatment with Fosamax and were not different with respect to gender and type of renal disease.

Table 2. Changes in dialysate electrolytes before and after Fosamax therapy

| Table | Before Fosamax | After Fosamax |
|-------|----------------|--------------|
| A- Hemodialysis group (n=105): |
| iCa 0 | iCa 0 | iCa 0 | iCa 4 |
| P 0 | P 4 | P 0 | P 4 |
| HCO 0 | HCO 0 | HCO 0 | HCO 4 |
| 1.75 | 1.82 (0.1) | 1.75 | 1.75 (0.4) |
| P 0 | 0.6 (0.2) | 0 | 0.5 (0.4) |
| HCO 0 | 32 | HCO 4 | 32 | 27 (2) |
| B- Hemodialfiltration group (n=44): |
| iCa 0 | iCa 0 | iCa 0 | iCa 4 |
| P 0 | P 4 | P 0 | P 4 |
| HCO 0 | HCO 0 | HCO 0 | HCO 4 |
| 1.75 | 1.8 (0.8) | 1.7 | 1.7 (0.6) |
| P 0 | 0.4 (0.4) | 0 | 0.3 (0.2) |
| HCO 0 | 32 | HCO 4 | 32 | 26 (2) |

Abbreviations: iCa, ionised calcium; P, phosphorus; HCO, bicarbonate.
Time of testing with regards dialytic therapy: at start (0), 4 hours later (4), 8 hours later (8)

DISCUSSION

In our study, hypercalcaemia developed during the 4 hours of both BPT then decreased subsequently yet remained significantly high 4 hours later. During BPT, serum Ca level was more than that in the initial dialysate fluid. Moreover, it’s concentration in the final dialysate was higher than that in the dialysate bags indicating Ca leak in dialysate during BPT. The only plausible source for such hypercalcemia is the patients’ bones. Confirmation of our theory came with repeating the investigations after treatment with Fosamax in an attempt to decrease the osteoclastic activity. After a single tablet of it; previous hypercalcemia was ameliorated. Unfortunately, Bisphosphonate therapy is not recommended, in patients with GFR < 30%, since renal excreted with potential risk for adynamic bone disease. However, some researchers have used Bisphosphonates successfully, at lower doses, to prevent hip fractures in this patient population. Moreover, Bisphosphonates have been shown to reduce vascular calcification via inhibition of the expression of TNF-α, which promotes osteoblastic differentiation, as well as calcium deposition in atheromatous lesions of rabbit aorta. The stimulus for bone resorption is intriguing yet is BPT-induced hypophosphataemia was the only plausible culprit. A recent study has shown an association between post-dialysis hypophosphataemia and low bone mineral density in chronic dialysis patients.

In conclusion: significant transient hypercalcemia has been observed during BPT and is associated with Ca loss in the dialysate fluid. Measures to assess and correct its long-term sequelae on vascular calcification and renal osteodystrophy are indicated.

REFERENCES:

1. Bryant JH, Hale-White W. A case of calcification of the arteries andobliterative endarteritis, associated with hydrophosphinosis, in a child aged six months. Guy’s Hosp Rep 1901; 40:17-28.
2. Mulligan, RM. Metastatic calcification. Arch Pathol 1946; 42:177-230.
3. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38:938-942.
4. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32:S112-119.
5. Hunt JL, Fairman R, Mitchell ME, Carpenter JP, Golden M, et al. Bone formation in carotid plaques: a clinicopathological study. Stroke 2002; 33:1214-1219.
6. Gachelli CM. The emerging role of phosphate in vascular calcification. Kidney Int 2009; 75:890-897.
7. Covic A, Kanabay M, Voroneau L, Turgut F, Serban DN, et al. Vascular calcification in chronic kidney disease. Clin Sci (London) 2010; 119:11-121.
8. Block GA, Port FK. Re-evaluation of risks associated with hyperparathyphemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management. Am J Kidney Dis 2000; 35:1226-1237.
9. Seitz SA, Speer MY, Curinga G, et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Osf1 and downregulation of smooth muscle lineage markers. Circ Res 2001; 89:1147-1154.
10. Proudfoot D, Skepern JN, Hegyi L, et al. Apoptosis regulates human vascular calcification in vitro - Evidence for initiation of vascular calcification by apoptotic bodies. Circ Res 2000; 87:1055-62.
11. Valdivielso JM. Vascular calcification: types and mechanisms. Nephrology 2011; 31:142-147.
12. Bisphosphonates in Chronic Kidney Disease: Balancing Potential Benefits and Adverse Effects on Bone and Soft Tissue. Nigel D, Toussaint, Grame J. Elder and Peter G. Kerr. GJASN 2009; 4:221-233.
13. Wetmore JR, Benet LZ, Kleinstuck D, Frassetto L: Effects of short-term alendronate on bone mineral density in haemodialysis patients. Nephrology (Carlton) 2005; 10:393-399.
14. Yilitalo R, Oksala O, Vila-Herttuila S, Ylitalo P: Effects of clodronate (dichloromethylene bisphosphonate) on the development of experimental atherosclerosis in rabbits. J Lab Clin Med 1994; 123:769-776.
15. Masakane I, Sakai Y, Suzuki E, Suzuki M, Natashima M. FP478: Post-dialysis hypophosphatemia might be a risk of losing bone density in chronic dialysis patients? 56th ERA-EDTA 2019 Congress Abstracts.